Faculty profile

Yuzhuo Wang

ResearcherUrologic SciencesUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses may be missing. Find their university profile.

Yuzhuo Wang

Researcher

Urologic Sciences

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
73 publications in the last five years, latest in 2026.
Senior (last) author on 20 recent papers, a sign of leading a research group.
Principal investigator on 17 research grants (17 CIHR), most recently in 2026.
Supervisor on 3 trainee awards (3 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

201

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Prostate Cancer Nepc Neuroendocrine Transdifferentiation Patient-Derived Xenografts Acidic Tumour Microenvironment Altered Cancer Metabolism Anticancer Immunity Cancer-Generated Lactic Acid

Latest papers

MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026
Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer.
JCI insight · 2026
A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer.
Cancer cell · 2026

All 201 publications

Latest funding

Derisking the Development of VPC-25959 Derivatives as Novel MCT4 Inhibitors for Clinical Trials in Patients with Advanced Glycolytic Cancers
CIHR · 2026 · Nominated PI
$1,912,500
Targeting Epigenetic Phenotypic Switching to Overcome Prostate Cancer Treatment Resistance
CIHR · 2025 · Co-investigator
$841,500
PROX1 Drives Cell Lineage Reprogramming in Neuroendocrine Prostate Cancer
CIHR · 2025 · Nominated PI
$1,166,625

All 29 grants and awards

From the 150 most recent of 201 publications.

MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer.

Liu W, He L, Zhong C, Wang Y, Zhang D, Mirza M, Li B

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2026

DOI: 10.1016/j.drup.2026.101463 PMID: 42546543

Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer.

Storck WK, Flores D, Kumaraswamy A, Duan Z, Chakraborty S, Zhang C, Rodansky E, Khokhani D, Swaim OA, Bedi K, Cavalcante RG, Chen C, Zhao F, Hu YM, Xia Z, Rebernick RJ, Cieslik M, Mannan R, Mahapatra S, Chinnaiyan AM, Udager AM, Kuleape JA, Alumkal CR, Beck HN, Nelson PS, Morrissey C, Haffner MC, Ellis L, Wang Y, Yates JA, Alumkal JJ

JCI insight2026

DOI: 10.1172/jci.insight.207543 PMID: 42579341

A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer.

Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karabürk H, Bhattacharyya R, Yin Y, Zhao Y, Liu W, Cao X, Xue H, Li C, Wang Z, Miner SJ, Reichert ZR, Mehra R, Vaishampayan U, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Chinnaiyan AM, Qiao Y

Cancer cell2026

DOI: 10.1016/j.ccell.2026.07.003 PMID: 42546705

Correction: Maylin et al. Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer. Cells 2024, 13, 1999.

Maylin ZR, Smith C, Classen A, Asim M, Pandha H, Wang Y

Cells2026Senior author

DOI: 10.3390/cells15181636 PMID: 42782819

Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.

Chen Z, Sayar E, Guevara D, Richards H, Zhang H, Patel RA, Gawne AC, Liu LJ, Coleman I, Dumpit R, Morrissey C, Schweizer MT, Raychaudhuri R, Graham LS, Yu EY, Cheng HH, Ding CC, Wang Y, Choyke P, Turkbey B, Chanel-Vos C, Fedorov C, Otilano Iii JR, Kane T, Manohar J, Sigouros M, Nauseef JT, Molina A, Nanus D, Tagawa ST, Mosquera JM, Beltran HP, Etzioni R, Nelson PS, Soundararajan R, Aparicio AM, Sternberg CN, Haffner MC, Harmon SA

JCI insight2026

DOI: 10.1172/jci.insight.201872 PMID: 42560769

Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer.

Brown LG, Coleman IM, Chu TLH, Sayar E, Patel RA, Hanratty B, Adil M, Li D, Li Y, Nguyen HM, Sessions CJ, Sweeney EL, Alumkal JJ, da Costa RMG, Wang Y, Lin DW, True LD, Dumpit R, Corey E, Lee JK, Nelson PS, Xin L, Haffner MC, Morrissey C

Neoplasia (New York, N.Y.)2026

DOI: 10.1016/j.neo.2026.101321 PMID: 42217442

DNMT3B drives neuroendocrine lineage plasticity and aggressive progression in prostate cancer.

Jo Y, Jung H, Wang Z, Lee D, Tran A, Tsai B, Zhao T, Huang F, Jung I, Hong C, Lim E, Dhandapani S, Wang Y, Wang Y, Huang J, Park JW

Molecular cancer research : MCR2026

DOI: 10.1158/1541-7786.mcr-25-1300 PMID: 42530436

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

Subramani E, Pilié PG, Slack-Tidwell R, Viscuse PV, Kuang X, Kandasamy T, Awad D, Han JJ, Huang L, Peterson CB, Zurita AJ, Subudhi SK, Corn PG, Soundararajan R, Shepherd P, Piyarathna B, Putluri V, Putluri N, Sreekumar A, Wang Y, Zoubeidi A, Mahmud I, Martinez SA, Tan L, Lorenzi PL, Basu S, Jindal S, Sharma P, Logothetis CJ, Thompson TC, Frigo DE, Aparicio AM

iScience2026

DOI: 10.1016/j.isci.2026.116184 PMID: 42291217

A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer.

Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karabürk H, Bhattacharyya R, Yin Y, Zhao Y, Liu W, Cao X, Xue H, Li C, Wang Z, Miner SJ, Vaishampayan U, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Qiao Y, Chinnaiyan AM

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.06.15.732391 PMID: 42528528

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.

Matsuoka T, Akamatsu S, Ong CJ, Gleave ME, Wang Y

Cells2026Senior author

DOI: 10.3390/cells15070588 PMID: 41972679

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2026

Subject: Prospective PhD student: Prostate Cancer Dear Professor Wang, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Derisking the Development of VPC-25959 Derivatives as Novel MCT4 Inhibitors for Clinical Trials in Patients with Advanced Glycolytic Cancers" (2026), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Yuzhuo Wang

Research

Latest papers

Latest funding

MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer.

Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer.

A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer.

Correction: Maylin et al. Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer. Cells 2024, 13, 1999.

Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.

Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer.

DNMT3B drives neuroendocrine lineage plasticity and aggressive progression in prostate cancer.

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer.

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.

Frequent collaborators

Martin Gleave

Colin Collins

Amina Zoubeidi

Xuesen Dong

Yu Wang

Mads Daugaard

Artem Cherkasov

Christopher Ong

Ralph Buttyan

Stephen Lam

Victor Ling

Alejandro Berlin

David Huntsman

Caigan Du

Michael Cox

Lucia Nappi

Yemin Wang

Gang Wang

Shoukat Dedhar

Marco Marra

Marianne Koritzinsky

Sebastien Hotte

Martin Hirst

Paul Rennie